These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2784908)

  • 1. Role of recombinant interleukin-2 (rIL-2) and large granular lymphocytes (LGLs) in acute rat graft-versus-host disease (GVHD).
    Clancy J; Goral J; Kovacs EJ; Ellis T
    Transplant Proc; 1989 Feb; 21(1 Pt 1):88-9. PubMed ID: 2784908
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-related injury to endothelium associated with acute graft-versus-host disease in the rat.
    Beschorner WE; Shinn CA; Hess AD; Suresch DL; Santos GW
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3025-7. PubMed ID: 2468250
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of donor pretreatment on graft-versus-host disease (GVHD) after rat small-bowel transplantation (SBTX).
    Matsumoto S; Tanaka S; Orita K
    Transplant Proc; 1994 Aug; 26(4):2306-8. PubMed ID: 8066758
    [No Abstract]   [Full Text] [Related]  

  • 5. Graft-versus-host and cytotoxic activity of rat thoracic duct lymphocytes fractionated by zonal centrifugation after culture on allogeneic fibroblasts.
    Bowers WE
    J Immunol; 1974 Oct; 113(4):1252-61. PubMed ID: 4153365
    [No Abstract]   [Full Text] [Related]  

  • 6. Mesenteric and intraepithelial lymphocytes are insufficient to cause rejection but able to mediate lethal graft-versus-host disease in small bowel transplants.
    Xia W; Brandeis JM; Sayegh M; Kirkman RL
    Transplant Proc; 1994 Jun; 26(3):1508-9. PubMed ID: 8030013
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.
    Weiss L; Slavin S
    Bone Marrow Transplant; 1999 Jun; 23(11):1139-43. PubMed ID: 10382953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung transplantation in the rat: cellular mechanisms of allograft rejection.
    Pepper JR; Parfett GJ; Reader JA; Kirby JA
    Transplant Proc; 1989 Feb; 21(1 Pt 1):470-2. PubMed ID: 2650180
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
    Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
    Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of cardiac allograft survival following intraportal injection of donor antigen is inhibited by cyclosporine A.
    Farges O; Buffello D; Shi YM; Moufetier A; Bismuth H
    Transplant Proc; 1995 Aug; 27(4):2525-7. PubMed ID: 7652915
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity.
    Ilan Y; Ohana M; Pappo O; Margalit M; Lalazar G; Engelhardt D; Rabbani E; Nagler A
    Transplantation; 2007 Feb; 83(4):458-67. PubMed ID: 17318079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etretinate (Ro 10-9359) prevents autoimmune syndrome associated with chronic graft-versus-host disease in rats.
    Stosić-Grujicić S; Ejdus L; Mijatović S; Jovanović S; Ostojić NS
    Transplant Proc; 1996 Dec; 28(6):3258. PubMed ID: 8962263
    [No Abstract]   [Full Text] [Related]  

  • 16. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.
    Ellison CA; Fischer JM; HayGlass KT; Gartner JG
    J Immunol; 1998 Jul; 161(2):631-40. PubMed ID: 9670937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
    Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
    Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor intrathymic injection with recipient splenocytes allows indefinite survival following small bowel transplantation in a rat graft-vs-host disease model.
    Blakely ML; Shaffer D; Ohzato H; Gottschalk R; Van der Werf WJ; Monaco AP
    Transplant Proc; 1994 Jun; 26(3):1582. PubMed ID: 8030046
    [No Abstract]   [Full Text] [Related]  

  • 19. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
    Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
    Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.